Efferon develops blood purification device for pediatric sepsis
Efferon, a Startup Battlefield 200 company, has created blood purification devices that remove both endotoxins and cytokines when standard sepsis treatments fail. Its pediatric device, Efferon NEO, received a CE mark in April and is used in intensive care units across 30 countries, with the company preparing an FDA filing. Efferon expects to reach $2 million in annualized revenue by the end of 2026, and its CEO says success is measured by children returning home.
Efferon, chosen for TechCrunch Disrupt 2026’s Startup Battlefield 200, focuses on sepsis, an infection-driven inflammatory reaction that kills roughly three million children under five each year. Its absorbers are built to remove endotoxins and cytokines at the same time when antibiotics and routine care cannot stop the immune system’s overreaction.
The pediatric version, Efferon NEO, received a CE mark in April and is described as the first blood-cleaning device for pediatric sepsis that targets multiple harmful substances. It is used in intensive care units in 30 countries, including parts of Europe, Saudi Arabia, and Thailand. Efferon is preparing an FDA filing and aims for a $2 million yearly revenue run rate by the end of 2026.
If Efferon NEO gains wider approval, critically ill children and their families may benefit from faster recovery and reduced organ failure, potentially easing ICU burdens. Clinicians could gain another option when standard sepsis care fails. Its impact may remain concentrated where devices are available and affordable, so access could shape how broadly these benefits are felt.